Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Myhibbin (mycophenolate mofetil) Oral Suspension for Prophylaxis of Organ Rejection
WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products...
US FDA Approves High-Concentration, Citrate-Free Formulation of Cyltezo (adalimumab-adbm) injection
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of...
Positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
STOCKHOLM, May 6, 2024. Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its...
Seven Percent of Outpatients Experience One or More Adverse Event
Among outpatients, 7.0 percent have at least one adverse event (AE), with adverse drug events being the most common, according to a study published online...
Racial, Ethnic Disparities Seen for Leading Causes of Youth Mortality
There are racial and ethnic disparities for nearly all leading causes of injury and disease tied to youth mortality, according to a study published online...
Mortality Risk Up for Cancer Survivors With Elevated Loneliness
Cancer survivors with elevated loneliness have a higher mortality risk, according to a study published online April 25 in the Journal of the National Comprehensive...
Doppler Ultrasound Feasible for First-Line Diagnosis of Giant Cell Arteritis
For patients with high clinical suspicion of giant cell arteritis (GCA), color Doppler ultrasound of the temporal artery as a first-line diagnostic tool...
Gene Therapy Improves Vision in People With Inherited Blindness
An injectable gene therapy caused measurable improvements in vision among a small group of people with inherited blindness, an early-stage clinical trial...
Parental Deaths to Guns, Drugs Harmed Nearly 100,000 U.S. Kids in 2020
Nearly 100,000 U.S. children lost a parent in 2020 to gun violence or drug overdose, a three-fold rise since 1999, according to a new study. Overall,...
Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Survey
Parents of newborns diagnosed with cystic fibrosis often are confused about both the disease and their next steps, a new national survey has found. In...
Avoid Some 'Project Watson' Dog Eye Wipes Due to Infection Danger
Pets and pet owners who come into contact with Bausch & Lomb's "Project Watson" dog eye wipes could be at risk for infection if the products come from...
Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published
SAN ANTONIO, May 3, 2024. Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment...
When in Life Are Folks Most Lonely?
At what age does loneliness strike adults the hardest? A new review maps it out, finding that people are more lonely as young adults, grow less lonely...
Recently Added
Recently added consumer and prescribing information: Myhibbin, Rezenopy, Libervant, Beqvez, Xolremdi, Pivya, Xromi, Risvan, Voydeya, Winrevair
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Myhibbin Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection.
- Libervant Libervant (diazepam) is a buccal film formulation of the benzodiazepine diazepam that may be given to treat children aged 2 to 5 years with...
- Xolremdi Xolremdi (mavorixafor) is a CXC chemokine receptor 4 (CXCR4) antagonist indicated in patients 12 years of age and older with WHIM syndrome...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to...